AAOpt: Presbyopia-correcting CSF-1 demonstrates consistent pupil restriction

News
Video

CSF-1 (0.4% pilocarpine HCl), a presbyopia-correcting drop candidate from Orasis, demonstrated consistent pupil restriction, which also suggests neuroadaptation in patients with presbyopia to the drop over time.

Jacob R. Lang, OD, FAAO, presented a poster at the 2023 American Academy of Optometry (AAOpt) meeting. The poster, entitled, "Persistence of Near Vision Improvement and Pupil Size: Results of the Pooled (NEAR) Phase 3 Studies of CSF-1 (0.4% pilocarpine HCl) for Presbyopia," details data on Orasis presbyopia-correcting drop candidate, which is expected to receive an FDA decision by the PDUFA date of October 22, 2023.

Video transcript

Editor's note: This transcript has been lightly edited for clarity.

Jacob R. Lang, OD, FAAO:
Hi, I'm Jacob Lang. I'm with Associated Eye Care in Stillwater, Minnesota and Hudson, Wisconsin. My poster is about CSF-1 and persistence of pupil change, as well as near adaptation that occurs with use of this presbyopia-correcting medication. In this research, we saw consistent pupil restriction, with pupils in the range of 2 to 3 millimeters at both one, eight, and 15 days. The percentage of 3 line responders improved from day 1 to day 8, and again from day 8 to 15.

Based on this improvement we saw over time, this may indicate nueroadaptation occurring in these presbiopic patients as they learn how this medication works and as their brains realize how to see better at near. I think this leads into further research and understanding how our brains really interact with our visual system especially, with near correction.

The future of presbyopia research is bright. I think there's a lot of demand [and] a lot of opportunity for improving our patients visions in this frustrating visual condition.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Dr Ashley Tucker Wallace discusses the intersection of pediatric dry eye and myopia control
Karen R. Hoffman, OD, speaks on her AOA 2025 poster, which details a case series on fitting patients with irregular cornea and astigmatism with Zenlens (Bausch + Lomb)
© 2025 MJH Life Sciences

All rights reserved.